Is Beijing Shenzhou Cell Biotechnology Group Co., Ltd. a listed company?

Beijing Shenzhou Cell Biotechnology Group Co., Ltd. is a listed company. The company was listed on the Science and Technology Innovation Board of Shanghai Stock Exchange on June 22, 2020 with the stock code of 688520. Beijing Shenzhou Cell Biotechnology Group Co., Ltd. was established on April 23, 2007. Its registered address is Room 307, Building 5, No.31Kechuang Seventh Street, Beijing Economic and Technological Development Zone, and its legal representative is Xie Liangzhi.

Company development process

On the evening of February 65438+2023 1 day, China Cell -U(688520. SH) disclosed the information that the self-developed COVID-19 vaccine was approved for emergency use.

On April 13, 2024, Shenzhou Cell released its 2023 annual report. During the reporting period, the company achieved revenue of188.7 billion yuan, up 84.46% year-on-year; The net profit attributable to shareholders of listed companies was-396 million yuan, and in 2022 it was-565,438+0.9 billion yuan, further narrowing the losses.

Honors won by the company

20 19165438+1October 15, Hurun Research Institute released "Shimao Strait 2019 Third Quarter Hurun Unicorn Index for Greater China", and Shenzhou Cell was listed at a valuation of 7 billion RMB. In June, 2023, it ranked 357th in the Hurun China Top 500 in 2022.

Business scope of the company

Research and development of biomedical products and vaccines: property management. (Enterprises independently choose business projects and carry out business activities according to law; Projects that must be approved according to law shall, after being approved by the relevant departments, carry out business activities in accordance with the approved contents; Shall not engage in business activities of projects prohibited and restricted by the industrial policies of this Municipality. )

company introduction

Beijing Shenzhou Cell Biotechnology Group Co., Ltd. is an innovative biopharmaceutical and vaccine research and development company founded by Dr. Xie Liangzhi, an internationally renowned expert in biopharmaceutical research and industrialization and an expert in the overall group of major new drug creation projects. Committed to developing products with differentiated competitive advantages, providing high-quality and low-price choices for patients at home and abroad, and establishing leading biopharmaceutical brands.

Since the establishment of Shenzhou Cell Engineering Co., Ltd., a subsidiary of the group, in 2002, the company has long insisted on independent research and development and mastered core technologies, established a set of upstream and downstream technology platforms for biopharmaceuticals and vaccines, and independently developed competitive and rich product pipelines, covering malignant tumors, autoimmune diseases, genetic diseases, disease prevention and other fields.

Company product research and development

The company's management team has rich experience in biopharmaceutical R&D and production. Dr. Xie Liangzhi, the founder of the company, successfully tried the complex, multivariable and stoichiometrically controlled fed-batch culture process of animal cells during his doctoral studies at MIT, which increased the antibody production from 50 mg/L of 1994 to 2400mg/L, laying an important foundation for the large-scale production of antibody drugs.

After returning to China in 2002, he undertook a number of national "863" plans and national "new drug creation" major projects; Led the team to establish a world-class biopharmaceutical R&D and industrialization technology platform, broke through a series of key technologies, and conquered recombinant coagulation factor 8 and long-acting interferon. Production technology of high-difficulty biopharmaceuticals such as HPV vaccine with titer of 14.

Dr. Wang Yang, deputy general manager of the company, has more than 20 years of experience in vaccine and antibody drug research and development and project management, and has led the quality analysis and quality standard formulation of cervical cancer vaccine. He is an internationally renowned expert in quality control of biopharmaceuticals.